RhumbLine Advisers’s Contineum Therapeutics CTNM Stock Holding History

RhumbLine Advisers’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,573	Closed	-$52.9K	–	4290
2025 Q1	$52.9K	Sell	7,573 -660	-8%	-$6K	﹤0.01%	3560
2024 Q4	$121K	Buy	8,233 +2,191	+36%	+$34.7K	﹤0.01%	3420
2024 Q3	$116K	Sell	6,042 -680	-10%	-$13K	﹤0.01%	3460
2024 Q2	$118K	Buy	+6,722	New	+$108K	﹤0.01%	3465

Other funds holding CTNM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RhumbLine Advisers's CTNM Position: Q2 2025 in Review

RhumbLine Advisers sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 7,573 shares — an estimated $52.9K sold.

RhumbLine Advisers first reported a position in CTNM in Q2 2024 and held it in 4 quarters. The position peaked at $121K in Q4 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

RhumbLine Advisers reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
RhumbLine Advisers sold 7,573 Contineum Therapeutics shares in Q2 2025, an estimated $52.9K.
RhumbLine Advisers first reported a position in Contineum Therapeutics in Q2 2024 and held it in 4 quarters.
RhumbLine Advisers's Contineum Therapeutics position peaked at $121K in Q4 2024.
70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.